Chemistry:Talnetant
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C25H22N2O2 |
| Molar mass | 382.463 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several functions (primarily treatment of irritable bowel syndrome, despite a 2007 study finding no statistically significant improvement in rectal hypersensitivity over placebo). Its use as a potential antipsychotic drug for the treatment of schizophrenia has also been discontinued.[1][2][3][4]
See also
References
- ↑ "UPDATE 1-GlaxoSmithKline prunes new drug pipeline". Reuters. Oct 15, 2007. https://www.reuters.com/article/glaxo-pipeline-idUSL152723420071015.
- ↑ "Talnetant GlaxoSmithKline". Current Opinion in Investigational Drugs 6 (7): 717–21. July 2005. PMID 16044668.
- ↑ "Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans". Neurogastroenterology and Motility 19 (9): 732–43. September 2007. doi:10.1111/j.1365-2982.2007.00934.x. PMID 17727393.
- ↑ "In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia". Neuropsychopharmacology 33 (7): 1642–52. June 2008. doi:10.1038/sj.npp.1301549. PMID 17728699.
 |  |
